Navigation Links
TechniKrom's Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Date:2/17/2009

GLENVIEW, Ill., Feb. 17 /PRNewswire/ -- TechniKrom, Inc. and Asahi Kasei Medical Co., Ltd., who have a longstanding partnership in the commercialization of equipment for use with Planova(TM) virus removal filters, have reached agreement for the transfer of TechniKrom's biopharmaceutical business to Asahi Kasei Medical's full ownership. The integration of operations will be marked by the formation of Asahi Kasei TechniKrom, Inc., a wholly owned subsidiary of Asahi Kasei Medical, on March 1, 2009. Financial terms were not disclosed.

The combination unites two market leaders in innovation: TechniKrom in the design, manufacture, and validation of custom biopharmaceutical processing equipment, and Asahi Kasei Medical in hollow-fiber and membrane adsorption technology. The unified product portfolio will further allow TechniKrom to advance its goal of contributing to human well-being by providing the biopharmaceutical industry with an expanded, integrated toolset to both lower the cost of drug manufacturing and achieve the highest innate drug product quality. "In addition to our existing products and services that we will continue to offer, we are extremely excited about the lineup of novel bioprocess separations products that Asahi Kasei TechniKrom will introduce over the coming months," said TechniKrom President and founder, Lou Bellafiore.

Asahi Kasei Medical's current business in the bioprocess field is centered on Planova(TM) filters and filtration systems for virus removal in the production of biopharmaceuticals. "The product line synergies with TechniKrom are a natural fit. This integration allows us to more seamlessly advance the worldwide expansion of our bioprocess operations with a base for the development, production, and sale of equipment and systems in the US, the world's leading biopharmaceuticals market," said Yasuyuki Yoshida, President of Asahi Kasei Medical.

Asahi Kasei TechniKrom will be headed by the current TechniKrom management team and will continue to operate from TechniKrom's Glenview, IL facility.

About TechniKrom

Founded in 1994, TechniKrom is a privately held, diversified engineering and qualification firm that provides technologically advanced blending, synthesis, filtration and purification equipment and services to the Biopharmaceutical, Pharmaceutical, and Nutraceutical Industries worldwide. TechniKrom equipment permits the lowest cost of production and highest innate product quality, especially in cGMP regulated environments. TechniKrom promotes the implementation of Manufacturing Science in biopharmaceutical manufacturing facilities.

For more information about TechniKrom, visit: http://www.technikrom.com.

About Asahi Kasei Group

The Asahi Kasei Group, headed by Asahi Kasei Corporation, is one of Japan's leading industrial groups, with consolidated sales of approximately US$17 billion. It provides innovative solutions based in chemistry and materials science to a diverse range of markets including fibers, chemicals, consumer products, housing, construction, electronics, and health care.

For more information about Asahi Kasei, visit: http://www.asahi-kasei.co.jp.


'/>"/>
SOURCE TechniKrom, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):